Content
February 2013, Volume 14, Issue 1
- 41-56 The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
by Frank Lichtenberg - 57-66 Valuing EQ-5D using Time Trade-Off in France
by Julie Chevalier & Gérard Pouvourville - 67-73 What can we learn from international comparisons of costs by DRG?
by M. Pirson & L. Schenker & D. Martins & Duong Dung & J. Chalé & P. Leclercq - 75-84 Determinants of household direct and indirect costs: an insight for health-seeking behaviour in Burkina Faso
by Tin Su & Steffen Flessa - 85-94 A cost-effectiveness analysis of the Incredible Years parenting programme in reducing childhood health inequalities
by Donal O’Neill & Sinéad McGilloway & Michael Donnelly & Tracey Bywater & Paul Kelly - 95-105 Body weight and health-related quality of life in Catalonia, Spain
by Juan Oliva-Moreno & Ana Gil-Lacruz - 107-115 Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall
by E. Wetering & E. Stolk & N. Exel & W. Brouwer - 117-131 Key issues in the design of pay for performance programs
by Frank Eijkenaar - 133-151 Food prices and overweight patterns in Italy
by L. Pieroni & D. Lanari & L. Salmasi
December 2012, Volume 13, Issue 6
- 677-682 The Grossman model after 40 years
by Peter Zweifel - 683-705 Informal caring-time and caregiver satisfaction
by Miriam Marcén & José Molina - 707-722 Measuring attitude toward social health insurance
by Chung-Ping Loh & Katrin Nihalani & Oliver Schnusenberg - 723-740 The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications
by José Rodríguez Barrios & Ferran Pérez Alcántara & Carlos Crespo Palomo & Paloma González García & Enrique Antón De Las Heras & Max Brosa Riestra - 741-754 Health care usage among immigrants and native-born elderly populations in eleven European countries: results from SHARE
by Aïda Solé-Auró & Montserrat Guillén & Eileen Crimmins - 755-767 Economic evaluation of pay-for-performance in health care: a systematic review
by Martin Emmert & Frank Eijkenaar & Heike Kemter & Adelheid Esslinger & Oliver Schöffski - 769-776 Patients whose GP knows complementary medicine tend to have lower costs and live longer
by Peter Kooreman & Erik Baars - 777-788 Paying informally in the Albanian health care sector: a two-tiered stochastic frontier model
by Sonila Tomini & Wim Groot & Milena Pavlova - 789-799 The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey
by Aleksandra Gajic & David Cameron & Jeremiah Hurley - 801-809 Cost effectiveness of golimumab for the treatment of active psoriatic arthritis
by Ewen Cummins & Christian Asseburg & Manishi Prasad & Jacqueline Buchanan & Yogesh Punekar - 811-818 Favourable cost-benefit in an early defibrillation programme using dual dispatch of ambulance and fire services in out-of-hospital cardiac arrest
by Björn Sund & Leif Svensson & Mårten Rosenqvist & Jacob Hollenberg - 819-826 Epilepsy in Sweden: health care costs and loss of productivity—a register-based approach
by Kristian Bolin & Anders Lundgren & Fredrik Berggren & Kristina Källén
October 2012, Volume 13, Issue 5
- 525-531 Health economics and health technology assessment in Central and Eastern Europe: a dose of reality
by L. Gulácsi & E. Orlewska & M. Péntek - 533-548 Assessing preferences for improved smoking cessation medications: a discrete choice experiment
by Joachim Marti - 549-560 Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching
by Laura Haas & Tom Stargardt & Jonas Schreyoegg - 561-568 Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort
by Anders Gustavsson & Linus Jönsson & Johan Parmler & Niels Andreasen & Carina Wattmo & Åsa Wallin & Lennart Minthon - 569-574 Does participation in clinical trials influence the costs of future management of patients?
by Anne Hvenegaard & Henrik Juhl & Andreas Habicht - 575-587 Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale
by John Brazier & Donna Rowen & Yaling Yang & Aki Tsuchiya - 589-603 Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
by Thomas Delea & Paul Tappenden & Oleg Sofrygin & Dominy Browning & Mayur Amonkar & Jon Karnon & Mel Walker & David Cameron - 605-614 Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy?
by Juan Oliva-Moreno - 615-621 Private health insurance: a role model for European health systems
by Christine Arentz & Johann Eekhoff & Susanna Kochskämper - 623-634 The sustainability of European health care systems: beyond income and aging
by Fabio Pammolli & Massimo Riccaboni & Laura Magazzini - 635-649 Medical guidelines, physician density, and quality of care: evidence from German SHARE data
by Hendrik Jürges & Vincent Pohl - 651-661 Genetic testing in the European Union: does economic evaluation matter?
by Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos - 663-676 The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
by Mehlika Toy & Fatih Onder & Ramazan Idilman & Gokhan Kabacam & Jan Richardus & Mithat Bozdayi & Meral Akdogan & Zarife Kuloglu & Aydan Kansu & Solko Schalm & Cihan Yurdaydin
August 2012, Volume 13, Issue 4
- 375-378 Coping with uncertainty on health decisions: assessing new solutions
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo Juárez-Castelló - 379-380 The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator
by Mattias Neyt & Ann Den Bruel - 381-391 Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
by Sarah Dewilde & Bernd Brüggenjürgen & Christoph Nienaber & Jochen Senges & Robert Welte & Stefan Willich - 393-407 In with the new: the determinants of prescribing innovation by general practitioners in Ireland
by Jane Bourke & Stephen Roper - 409-417 On the meaningfulness of testing preference axioms in stated preference discrete choice experiments
by Jens Hougaard & Tue Tjur & Lars Østerdal - 419-427 Factors determining access to and use of primary health care services in the Girona Health Region (Spain)
by Carme Saurina & Laura Vall-llosera & Marc Saez - 429-443 Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease
by Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples - 445-450 Cost–effectiveness of statins revisited: lessons learned about the value of innovation
by Peter Lindgren & Bengt Jönsson - 451-460 The effect of health shocks on smoking and obesity
by Leonie Sundmacher - 461-490 The trade-off between formal and informal care in Spain
by Sergi Jiménez-Martín & Cristina Prieto - 491-500 The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design
by Arthur Attema & Werner Brouwer - 501-510 A proposed model for economic evaluations of major depressive disorder
by Hossein Haji Ali Afzali & Jonathan Karnon & Jodi Gray - 511-524 Cost of care for colorectal cancer in Ireland: a health care payer perspective
by L. Tilson & L. Sharp & C. Usher & C. Walsh & Whyte S & A. O’Ceilleachair & C. Stuart & B. Mehigan & M. John Kennedy & P. Tappenden & J. Chilcott & A. Staines & H. Comber & M. Barry
June 2012, Volume 13, Issue 3
- 223-226 Time to incorporate time in cost-effectiveness analysis
by Gijs Wetering & Willem Woertman & Eddy Adang - 227-236 Smoking bans and the secondhand smoking problem: an economic analysis
by Annette Hofmann & Martin Nell - 237-250 Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer
by Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach - 251-265 I feel good! Gender differences and reporting heterogeneity in self-assessed health
by Udo Schneider & Christian Pfarr & Brit Schneider & Volker Ulrich - 267-276 Socioeconomic analysis of patient-centric networks: effects of patients and hospitals’ characteristics and network structure on hospitalization costs
by Alireza Abbasi & Shahadat Uddin & Liaquat Hossain - 277-287 The demand for sports and exercise: results from an illustrative survey
by Nana Anokye & Subhash Pokhrel & Martin Buxton & Julia Fox-Rushby - 289-300 Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network
by Nathalie Havet & Magali Morelle & Raphaël Remonnay & Marie-Odile Carrere - 301-313 Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data
by Maria-Isabel Farfan-Portet & Carine Van de Voorde & France Vrijens & Robert Vander Stichele - 315-325 Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data
by France Vrijens & Carine Van de Voorde & Maria-Isabel Farfan-Portet & Robert Vander Stichele - 327-336 Formal and informal care for disabled elderly living in the community: an appraisal of French care composition and costs
by Alain Paraponaris & Bérengère Davin & Pierre Verger - 337-346 Impact of healthcare reforms on out-of-pocket health expenditures in Turkey for public insurees
by Burcay Erus & Nazli Aktakke - 347-353 Lifetime costs of the top five cancers in Taiwan
by Hui-Chu Lang & Shi-Liang Wu - 355-363 Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis
by Lone Baandrup & Jan Sørensen & Henrik Lublin & Merete Nordentoft & Birte Glenthoj - 365-374 Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
by Galin Michailov & Glenn Davies & Karl Krobot
April 2012, Volume 13, Issue 2
- 121-126 Separating the wheat from the chaff
by Claus Runge - 127-144 Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis
by Mareike Schad & Jürgen John - 145-156 Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
by Christopher Knight & Josephine Mauskopf & Mats Ekelund & Amitabh Singh & Shiyi Yang & Robert Boggs - 157-167 Malpractice liability, technology choice and negative defensive medicine
by Eberhard Feess - 169-180 Decision-making in general practice: the effect of financial incentives on the use of laboratory analyses
by Siri Munkerud - 181-192 Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam
by Steven Edwards & Sarah Wordsworth & Mike Clarke - 193-202 Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence
by Oliver Reich & Cornelia Weins & Claudia Schusterschitz & Magdalena Thöni - 203-221 Defining care products to finance health care in the Netherlands
by Machiel Westerdijk & Joost Zuurbier & Martijn Ludwig & Sarah Prins
February 2012, Volume 13, Issue 1
- 1-5 Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
by Michael Drummond & Adrian Towse - 7-18 The convergence of health care financing structures: empirical evidence from OECD-countries
by Andrea Leiter & Engelbert Theurl - 19-27 Decomposing the determinants of health care expenditure: the case of Spain
by David Prieto & Santiago Lago-Peñas - 29-38 The impact of presumed consent laws and institutions on deceased organ donation
by Fırat Bilgel - 39-50 The impact of BMI on direct costs in Children and Adolescents: empirical findings for the German Healthcare System based on the KiGGS-study
by Christina Wenig - 51-62 Spillover effects of supplementary on basic health insurance: evidence from the Netherlands
by Anne-Fleur Roos & Frederik Schut - 63-70 Future costs in cost-effectiveness analysis: an empirical assessment
by Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen - 71-80 Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy
by O. Zaniolo & S. Iannazzo & L. Pradelli & M. Miravitlles - 81-91 The cost of multiple sclerosis in Norway
by B. Svendsen & K.-M. Myhr & H. Nyland & J. Aarseth - 93-99 Do smoke-free laws affect revenues in pubs and restaurants?
by Hans Melberg & Karl Lund - 101-110 Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
by I. Lenoir-Wijnkoop & W. Aalderen & G. Boehm & D. Klaassen & A. Sprikkelman & M. Nuijten - 111-120 Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications
by Nick Kontodimopoulos & Evelina Pappa & Zinovia Chadjiapostolou & Eleni Arvanitaki & Angelos Papadopoulos & Dimitris Niakas
December 2011, Volume 12, Issue 6
- 499-502 Budget impact analysis in economic evaluation: a proposal for a clearer definition
by Livio Garattini & Katelijne Vooren - 503-508 Comparison of cost-weights scales methodologies in the perspective of a financing system based on pathologies
by M. Pirson & C. Delo & D. Martins & P. Leclercq - 509-519 Cost efficiency of university hospitals in the Nordic countries: a cross-country analysis
by Emma Medin & Kjartan Anthun & Unto Häkkinen & Sverre Kittelsen & Miika Linna & Jon Magnussen & Kim Olsen & Clas Rehnberg - 521-531 Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience
by Paul Gorecki - 533-539 Direct costs of Alzheimer’s disease in Germany
by Peter Kiencke & Dietmar Daniel & Christine Grimm & Reinhard Rychlik - 541-551 Exploring the relationship between costs and quality: Does the joint evaluation of costs and quality alter the ranking of Danish hospital departments?
by Anne Hvenegaard & Jacob Arendt & Andrew Street & Dorte Gyrd-Hansen - 553-562 How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives
by Özden Gür Ali & Başak Topaler - 563-573 The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain
by Iván Moreno-Torres & Jaume Puig-Junoy & Josep Raya - 575-588 Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
by M. Botteman & M. Meijboom & I. Foley & J. Stephens & Y. Chen & S. Kaura - 589-603 Market structure and hospital–insurer bargaining in the Netherlands
by R. Halbersma & M. Mikkers & E. Motchenkova & I. Seinen
October 2011, Volume 12, Issue 5
- 393-395 Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad
by Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas - 397-404 Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor
by Pepijn Vemer & Maureen Rutten-van Mölken - 405-416 Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals
by Christoph Schwierz & Achim Wübker & Ansgar Wübker & Björn Kuchinke - 417-427 Hospital’s activity-based financing system and manager: physician interaction
by David Crainich & Hervé Leleu & Ana Mauleon - 429-444 Contractual conditions, working conditions and their impact on health and well-being
by Silvana Robone & Andrew Jones & Nigel Rice - 445-453 Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare
by Tina Olsson - 455-467 Cost of low back pain in Switzerland in 2005
by Simon Wieser & Bruno Horisberger & Sara Schmidhauser & Claudia Eisenring & Urs Brügger & Andreas Ruckstuhl & Jürg Dietrich & Anne Mannion & Achim Elfering & Özgür Tamcan & Urs Müller - 469-478 Ageing and health care expenditure in EU-15
by Mickael Bech & Terkel Christiansen & Ehsan Khoman & Jørgen Lauridsen & Martin Weale - 479-487 Atrial fibrillation: the cost of illness in Sweden
by Lisa Ericson & Lennart Bergfeldt & Ingela Björholt - 489-497 Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients
by C. Sabariego & M. Brach & P. Herschbach & P. Berg & G. Stucki
August 2011, Volume 12, Issue 4
- 285-288 What values do the public want their health care systems to use in evaluating technologies?
by Martin Buxton & James Chambers - 289-295 Estimates of patient costs related with population morbidity: can indirect costs affect the results?
by M. Carreras & M. García-Goñi & P. Ibern & J. Coderch & L. Vall-Llosera & J. Inoriza - 297-309 Incentives in primary care and their impact on potentially avoidable hospital admissions
by Gianluca Fiorentini & Elisa Iezzi & Matteo Lippi Bruni & Cristina Ugolini - 311-317 The costs of breast cancer prior to and following diagnosis
by Steven Broekx & Elly Hond & Rudi Torfs & Anne Remacle & Raf Mertens & Thomas D’Hooghe & Patrick Neven & Marie-Rose Christiaens & Steven Simoens - 319-329 Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges
by Raymond Oppong & Joanna Coast & Kerry Hood & Jacqui Nuttall & Richard Smith & Christopher Butler - 331-344 Age effects in monetary valuation of reduced mortality risks: the relevance of age-specific hazard rates
by Andrea Leiter - 345-352 Health burden and costs of obesity and overweight in Germany
by A. Konnopka & M. Bödemann & H.-H. König - 353-361 Additional costs of inpatient malnutrition, Victoria, Australia, 2003–2004
by D. Rowell & T. Jackson - 363-371 Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data
by Laurent Molinier & Christel Castelli & Eric Bauvin & Xavier Rebillard & Michel Soulié & Jean-Pierre Daurès & Pascale Grosclaude - 373-381 Factors associated with the use of primary care services: the role of practice nurses
by Laura Vallejo-Torres & Stephen Morris - 383-391 The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure
by Nick Kontodimopoulos & Michalis Argiriou & Nikolaos Theakos & Dimitris Niakas
June 2011, Volume 12, Issue 3
- 189-191 To model or not to model: lessons from two vaccinations
by Livio Garattini & Anna Padula - 193-203 Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma
by Axel Mühlbacher & Matthias Nübling - 205-218 Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy
by Eberhard Wille & Jürgen Scholze & Eduardo Alegria & Claudio Ferri & Sue Langham & Warren Stevens & David Jeffries & Kerstin Uhl-Hochgraeber - 219-230 Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
by Kristina Boye & Louis Matza & Kimberly Walter & Kate Brunt & Andrew Palsgrove & Aodan Tynan - 231-241 Practical issues in handling data input and uncertainty in a budget impact analysis
by M. Nuijten & T. Mittendorf & U. Persson - 243-252 Deriving reference values and utilities for the QoL-AGHDA in adult GHD
by J. Busschbach & B. Wolffenbuttel & L. Annemans & W. Meerding & M. Kołtowska-Häggström - 253-261 Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece
by Nikos Maniadakis & Mattias Ekman & Vasilios Fragoulakis & Vasiliki Papagiannopoulou & John Yfantopoulos - 263-271 Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
by Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt - 273-283 Health care costs and their predictors of inflammatory bowel diseases in Germany
by Anne Prenzler & Bernd Bokemeyer & J.-Matthias Schulenburg & Thomas Mittendorf
April 2011, Volume 12, Issue 2
- 97-102 Relative effectiveness and the European pharmaceutical market
by Bengt Jönsson - 103-113 The effect of alcoholic beverage excise tax on alcohol-attributable injury mortalities
by Chong Son & Kudret Topyan - 115-125 Technical efficiency in primary health care: does quality matter?
by Luis Murillo-Zamorano & Carmelo Petraglia - 127-140 Economic policies for healthier food intake: the impact on different household categories
by Jonas Nordström & Linda Thunström - 141-162 Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness
by Nigel Rice & Silvana Robone & Peter Smith - 163-174 Severity as an independent determinant of the social value of a health service
by Jeff Richardson & John McKie & Stuart Peacock & Angelo Iezzi - 175-188 Trust on doctor, social capital and medical care use of the elderly
by Jae-Young Lim & Hyun-Hoon Lee & Yeon-Hee Hwang
February 2011, Volume 12, Issue 1
- 1-1 Letter from the editors
by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 3-16 Public health care providers and market competition: the case of Finnish occupational health services
by Eila Kankaanpää & Ismo Linnosmaa & Hannu Valtonen - 17-28 Inequalities in the use of health services between immigrants and the native population in Spain: what is driving the differences?
by Dolores Jiménez-Rubio & Cristina Hernández-Quevedo - 29-38 Health care expenditures and gross domestic product: the Turkish case
by Seher Sülkü & Asena Caner - 39-47 Optimal deductibles for outpatient services
by Karl-Michael Ortmann - 49-59 Generic substitution: micro evidence from register data in Norway
by Dag Dalen & Kari Furu & Marilena Locatelli & Steinar Strøm - 61-77 Social health inequalities among older Europeans: the contribution of social and family background
by Sandy Tubeuf & Florence Jusot - 79-85 Risk and uncertainty in health investment
by Takao Asano & Akihisa Shibata - 87-95 Preferences for health insurance and health status: does it matter whether you are Dutch or German?
by Janet Vroomen & Peter Zweifel
December 2010, Volume 11, Issue 6
- 521-523 A French approach to cost-effectiveness analysis?
by Gérard Pouvourville - 525-531 The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration
by Kathleen Ke - 533-541 Adolescents alcohol-use and economic conditions: a multilevel analysis of data from a period with big economic changes
by Mikael Svensson & Curt Hagquist - 543-554 The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands
by Marcus Keogh-Brown & Richard Smith & John Edmunds & Philippe Beutels - 555-568 The effect of health care expenditure on sickness absence
by David Granlund - 569-584 The sustainability of public health expenditures: evidence from the Canadian federation
by Livio Di Matteo - 585-594 The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
by Michael Willis & Marianne Svensson & Mickael Löthgren & Bo Eriksson & Anders Berntsson & Ulf Persson - 595-596 On the welfare theoretic foundation of CEA: comment
by Friedrich Breyer - 597-598 Cost-effectiveness analysis, welfare economics, and the societal perspective: a reply
by Bengt Liljas - 599-599 Erratum to: Hospital’s activity-based financing system and manager–physician interaction
by David Crainich & Hervé Leleu & Ana Mauleon
October 2010, Volume 11, Issue 5
- 435-435 EJHE has an official impact factor of 1.337
by J.-Matthias Graf von der Schulenburg - 437-447 Health insurance for the poor: impact on catastrophic and out-of-pocket health expenditures in Mexico
by Omar Galárraga & Sandra Sosa-Rubí & Aarón Salinas-Rodríguez & Sergio Sesma-Vázquez - 449-455 Expenditures of the German statutory health insurance system for patients suffering from acute coronary syndrome and treated with percutaneous coronary intervention
by Heiko Friedel & Anne Delges & Johannes Clouth & Dana Trautvetter - 457-469 Health impairments and labour market outcomes
by Nick Drydakis - 471-485 Onset of disability and life satisfaction: evidence from the German Socio-Economic Panel
by Ricardo Pagán-Rodríguez - 487-498 Health care utilisation and immigration in Spain
by José-Ignacio Antón & Rafael Muñoz de Bustillo - 499-511 Use of formal and informal care services among older people in Ireland and France
by Brenda Gannon & Bérengère Davin - 513-520 Spanish recommendations on economic evaluation of health technologies
by Julio López-Bastida & Juan Oliva & Fernando Antoñanzas & Anna García-Altés & Ramón Gisbert & Javier Mar & Jaume Puig-Junoy
August 2010, Volume 11, Issue 4
- 351-353 Feeding the economics of obesity in the EU in a healthy way
by Fernando Antonanzas & Roberto Rodríguez - 355-365 Optimal savings and health spending over the life cycle
by Tamara Fioroni - 367-381 The challenge of corporatisation: the experience of Portuguese public hospitals
by Guilhermina Rego & Rui Nunes & José Costa - 383-393 Geographic distribution of physicians in Portugal
by Correia Isabel & Veiga Paula - 383-393 Geographic distribution of physicians in Portugal
by Isabel Correia & Paula Veiga - 395-404 Substituting inpatient for outpatient care: what is the impact on hospital costs and efficiency?
by Kirsi Vitikainen & Miika Linna & Andrew Street - 405-412 Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain
by Juan Oliva-Moreno & Julio López-Bastida & Pedro Serrano-Aguilar & Lilisbeth Perestelo-Pérez - 413-418 Adverse selection in the health insurance market: some empirical evidence
by Marcelo Resende & Rodrigo Zeidan - 419-426 Modeling stroke management: a qualitative review of cost-effectiveness analyses
by Chantal Guilhaume & Delphine Saragoussi & John Cochran & Clément François & Mondher Toumi - 427-434 Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences
by Ralph Crott & Andrew Briggs
June 2010, Volume 11, Issue 3
- 235-238 Future challenges for health economics and health technology assessment of biological drugs
by László Gulácsi - 239-253 BMI and Spanish labour status: evidence by gender from the city of Barcelona
by Toni Mora - 255-266 The impact of missing data in the estimation of concentration index: a potential source of bias
by Hai Zhong - 267-277 The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
by Tom Stargardt - 279-290 Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes
by Yi-Wen Tsai & Yu-Wen Wen & Weng-Foung Huang & Ken Kuo & Pei-Fen Chen & Hsin-Wei Shih & Yue-Chune Lee - 291-304 Principal agent relationships and the efficiency of hospitals
by Martijn Ludwig & Frits Merode & Wim Groot - 305-322 The welfare costs of HIV/AIDS in Eastern Europe: an empirical assessment using the economic value-of-life approach
by Julia Fimpel & Michael Stolpe - 323-330 Eliciting health state utilities from the general public for severe chronic pain
by S. Eldabe & A. Lloyd & L. Verdian & M. Meguro & G. Maclaine & S. Dewilde - 331-341 Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach
by Jonas Schreyögg & Markus Grabka - 343-350 The Irish ‘health basket’: a basket case?
by Samantha Smith
April 2010, Volume 11, Issue 2
- 117-118 US health care reform: a work in progress
by Sean Sullivan - 119-126 Inpatient length of stay: a finite mixture modeling analysis
by Chungkham Singh & Laishram Ladusingh - 127-140 In which ways do unhealthy people older than 50 exit the labour market in France?
by Thomas Barnay - 141-150 The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population
by Dieter Tscheulin & Florian Drevs - 151-160 Interactions between cigarette and alcohol consumption in rural China
by Xiaohua Yu & David Abler - 161-175 Primary care delivery, risk pooling and economic efficiency
by Michael Leung - 177-184 Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study
by Lars Wilhelmsen & Lennart Welin & Anders Odén & Arne Björnberg - 185-193 Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study
by Greg Lissovoy & Kathy Fraeman & John Teerlink & John Mullahy & Jeff Salon & Raimund Sterz & Amy Durtschi & Robert Padley - 195-203 A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
by Ulf Persson & Michael Willis & Knut Ödegaard - 205-213 A social preference valuations set for EQ-5D health states in Flanders, Belgium
by Irina Cleemput - 215-225 A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures
by John Brazier & Yaling Yang & Aki Tsuchiya & Donna Rowen - 227-233 Health insurance in Croatia: dynamics and politics of balancing revenues and expenditures
by Luka Voncina & Jenni Kehler & Tamas Evetovits & Mario Bagat
February 2010, Volume 11, Issue 1
- 1-3 HTA in Germany: very special and specific
by Wolfgang Greiner & J.-Matthias Schulenburg - 5-13 On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected
by Bengt Liljas - 15-25 Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach
by Jan Jürgensen & Wolfgang Arns & Bastian Haß - 27-34 Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study
by Feng Xie & Ngai-Nung Lo & Jean-Eric Tarride & Daria O’Reilly & Ron Goeree & Hin-Peng Lee - 35-44 Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective
by Montserrat Vera-Llonch & Ellen Dukes & Javier Rejas & Oleg Sofrygin & Marko Mychaskiw & Gerry Oster - 45-55 The added value of thorough economic evaluation of telemedicine networks
by Myriam Le Goff-Pronost & Claude Sicotte - 57-66 An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?
by Rachel Elliott & Helen Weatherly & Neil Hawkins & Gillian Cranny & Duncan Chambers & Lindsey Myers & Alison Eastwood & Mark Sculpher - 67-76 Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
by Yogesh Punekar & Neil Hawkins - 77-94 Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings
by Harald Hamre & Claudia Witt & Anja Glockmann & Renatus Ziegler & Gunver Kienle & Stefan Willich & Helmut Kiene - 95-104 Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure
by Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth - 105-115 Cost effectiveness of palivizumab in Spain: an analysis using observational data
by Mark Nuijten & Wolfgang Wittenberg